Plus Therapeutics (PSTV) announces it has received an additional 180-day extension period from the Nasdaq Listing Qualifications Department to regain compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics highlights ReSPECT-LM trial results at SITC meeting
- Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning
- Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
- Plus Therapeutics Signs Lease Agreement in Houston
- Plus Therapeutics provides update on CNSide Diagnostic platform launch